| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aac4a747e60a2949ac458ccdbb76fdea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a77b8cc427db284b23b54636b37e89a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86c227a1644c83553c5f9b1fba0fa63d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-10 |
| filingDate |
2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ca0e1ab9cb68696b66cab65f1ffbee5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa21459e84e7fa03f9e7b4a28ad0db6a |
| publicationDate |
2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012067912-A1 |
| titleOfInvention |
Local vascular delivery of adenosine a2a receptor agonists to reduce myocardial injury |
| abstract |
A stent or other implantable medical device for the local delivery of a selective adenosine receptor agonist may be utilized to reduce myocardial injury following an acute myocardial infarction. As soon as possible following an acute myocardial infarction a stent or other suitable device comprising and capable of delivering a selective adenosine receptor agonist is positioned in the blood vessel with the occlusion responsible for causing the infarct. Once in position, the stent or other intraluminal device is deployed to remove the occlusion and reestablish blood flow to the specific area, region or tissue volume of the heart. Over a given period of time the selective adenosine receptor agonist elutes from the stent or other device into the downstream coronary blood flow into the hypoxic cardiac tissue for a time sufficient to reduce the level of myocardial injury. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10004509-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980663-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10806458-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11596409-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11712230-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11724075-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11344307-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10864106-B2 |
| priorityDate |
2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |